知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

102 条记录 (耗时 0.062 秒)

    Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method
    22.
    发明授权
    Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method 有权
    用于确定用于医学诊断目的的内皮素形成的方法，以及用于进行这种方法的抗体和试剂盒

    公开(公告)号：US08450463B2

    公开(公告)日：2013-05-28

    申请号：US13398211

    申请日：2012-02-16

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： C07K16/00

    CPC分类号： C07K16/00 ,  G01N33/57488 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/5754 ,  Y10S435/975

    摘要： Described herein is an in vitro method for the determination of the formation of endothelins in serious diseases, in particular cardiovascular diseases, inflammations, sepsis and cancer, in whole blood, plasma or serum of a human patient, in which relatively long-lived peptide fragments of the processed primary prepro- or proendothelins are determined which contain neither the actual biologically active endothelin nor its direct precursor big endothelin. In particular, disclosed are antibodies and kits for selectively detecting these fragments.

    摘要翻译： 本文描述的是用于测定人类患者的全血，血浆或血清中严重疾病，特别是心血管疾病，炎症，败血症和癌症中内皮素形成的体外方法，其中相对长寿的肽片段 的被处理的原始前原或前内皮素被确定为既不含实际的生物活性内皮素也不包含其直接前体大内皮素。 特别地，公开了用于选择性检测这些片段的抗体和试剂盒。

    Diagnosis and risk stratification by determining the marker CT-proADM
    23.
    发明授权
    Diagnosis and risk stratification by determining the marker CT-proADM 有权
    通过确定标记CT-proADM进行诊断和危险分层

    公开(公告)号：US08436135B2

    公开(公告)日：2013-05-07

    申请号：US12520159

    申请日：2007-12-20

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： A61K38/00

    CPC分类号： G01N33/6884 ,  C07K14/47 ,  C07K14/575 ,  C07K16/26 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/47 ,  G01N2800/12 ,  G01N2800/32

    摘要： The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No, 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.

    摘要翻译： 本发明涉及用于诊断和/或分层疾病风险的新型诊断标记物CT-proADM（preproADM的C末端片段，SEQ ID NO：1）。 还公开了用于诊断和/或分层疾病，特别是心血管疾病，心脏功能不全以及肺和呼吸道的感染和/或炎症的风险的方法。 在所述方法中，在待检查的患者中确定CT-proADM（SEQ ID No.1）标记或其片段的部分肽或包含在标记组合（面板，群集）中的所述标记。 本发明还涉及诊断装置以及用于执行所述方法的套件。

    Antibodies for the selective determination of procalcitonin 1-116
    24.
    发明授权
    Antibodies for the selective determination of procalcitonin 1-116 有权
    用于选择性测定降钙素原的抗体1-116

    公开(公告)号：US08354506B2

    公开(公告)日：2013-01-15

    申请号：US12529089

    申请日：2008-02-21

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： C07K16/26

    CPC分类号： G01N33/6854 ,  C07K16/26 ,  C07K2317/34 ,  G01N33/74 ,  G01N2333/585

    摘要： The present invention provides an immunodiagnostic method for determining procalcitonin and procalcitonin derivatives in a biological sample of a patient for diagnostic purposes, in particular in the monitoring and control of treatment and the monitoring of the progression of a local or systemic bacterial infection, inflammation, sepsis or neurodegenerative disease. In particular, the method detects molecular forms of procalcitonin, or procalcitonin partial peptides derived therefrom, having the amino acids alanine and proline (Ala-Pro, AP) in positions 1 and 2 of the amino terminus of the complete procalcitonin 1-116 (SEQ ID NO: 1.) Also disclosed are antibodies and kits for carrying out such a method.

    摘要翻译： 本发明提供了用于诊断目的的用于确定患者生物样品中的降钙素原和降钙素原衍生物的免疫诊断方法，特别是在监测和控制治疗以及监测局部或全身细菌感染，炎症，败血症 或神经变性疾病。 特别地，该方法检测在完全降钙素原1-116（SEQ ID NO：1）的氨基末端位置1和2中具有氨基酸丙氨酸和脯氨酸（Ala-Pro，AP）的降钙素原或降钙素原部分肽的分子形式 ID NO：1）还公开了用于进行这种方法的抗体和试剂盒。

    In vitro method for the detection of early-stage liver damage
    25.
    发明授权
    In vitro method for the detection of early-stage liver damage 有权
    用于检测早期肝损伤的体外方法

    公开(公告)号：US08252548B2

    公开(公告)日：2012-08-28

    申请号：US12299829

    申请日：2007-05-08

    申请人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler

    发明人： Andreas Bergmann ,  Joachim Struck ,  Nils G. Morgenthaler

    IPC分类号： C12Q1/34

    CPC分类号： G01N33/6893 ,  G01N2800/085

    摘要： Disclosed is an in vitro method for the identification and the concomitant monitoring of the therapy and cure of drug-induced or addictive substance-induced liver damage, in which the occurrence of the human enzyme carbamoyl synthase 1 (CPS 1) or its concentration is determined in serum or plasma samples from patients who are being or have been treated with potentially liver-damaging drugs, or from people who take harmful stimulants and addictive substances or are exposed to hepatotoxic substances.

    摘要翻译： 公开了一种用于鉴定和伴随监测药物诱导或成瘾物质诱导的肝损伤的治疗和治疗的体外方法，其中确定人酶氨基甲酰合酶1（CPS 1）或其浓度的发生 来自患有或已经被潜在的肝损伤药物治疗的患者的血清或血浆样品，或者来自服用有害兴奋剂和成瘾物质或暴露于肝毒性物质的人。

    Method for Detecting Analytes
    30.
    发明申请
    Method for Detecting Analytes 有权
    检测分析物的方法

    公开(公告)号：US20110020833A1

    公开(公告)日：2011-01-27

    申请号：US12666024

    申请日：2008-06-20

    申请人： Andreas Bergmann ,  Joachim Struck

    发明人： Andreas Bergmann ,  Joachim Struck

    IPC分类号： G01N33/53 ,  G01N33/543 ,  G01N30/00 ,  G01N31/22

    CPC分类号： G01N33/54306

    摘要： The subject of this invention is a process for detection of analytes from biological samples comprising the following process steps: a) Preparation of a reversible binding partner 1 that is immobilized on a solid phase, to which an analyte binder is reversibly bonded via a reversible binding partner 2 that is bonded to the analyte binder, whereby the analyte binder is immobilized by binding between the reversible binding partners 1 and 2, b) Addition of the biological sample and binding of the analyte to the reversible immobilized analyte binder in the case that the biological sample contains the analytes, c) Separation of the biological sample, d) Addition of a dissolving buffer, which dissolves the binding between the reversible binding partners 1 and 2, whereby the binding of the analyte to the analyte binder remains optional, and e) Detection of the analyte in the dissolving buffer in the case that the biological sample contains the analytes and determination of the absence of the analyte in the case that the biological sample does not contain the analytes, respectively.

    摘要翻译： 本发明的主题是用于检测来自生物样品的分析物的方法，包括以下过程步骤：a）固定在固相上的可逆结合配偶体1的制备，分析物粘合剂通过可逆结合可逆地结合到其上 配偶体2，其结合到分析物粘合剂上，由此通过可逆结合配偶体1和2之间的结合固定分析物粘合剂，b）添加生物样品并将分析物与可逆固定的分析物结合物结合， 生物样品含有分析物，c）生物样品的分离，d）加入溶解缓冲液，其溶解可逆结合配偶体1和2之间的结合，由此分析物与分析物质粘合剂的结合仍然是可选的，e ）在生物样品含有分析物和确定不存在分析物的情况下，检测溶解缓冲液中的分析物 在生物样品不分别含有分析物的情况下分析物。